Bdr International Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-12-2024
- Paid Up Capital ₹ 1.00 M
as on 03-12-2024
- Company Age 6 Year, 29 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 40.88%
(FY 2022)
- Profit 205.54%
(FY 2022)
- Ebitda 233.70%
(FY 2022)
- Net Worth 53.71%
(FY 2022)
- Total Assets 63.90%
(FY 2022)
About Bdr International Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Jivansing Rajput and Neelam Rajput serve as directors at the Company.
- CIN/LLPIN
U85200MH2018PTC318644
- Company No.
318644
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2018
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bdr International Diagnostics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jivansing Rajput  | Director | 21-Dec-2018 | Current |
| Neelam Rajput | Director | 21-Dec-2018 | Current |
Financial Performance of Bdr International Diagnostics.
Bdr International Diagnostics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.88% increase. The company also saw a substantial improvement in profitability, with a 205.54% increase in profit. The company's net worth Soared by an impressive increase of 53.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bdr International Diagnostics?
In 2019, Bdr International Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Neuron International Foundation LlpActive 8 years 7 monthsJivansing Rajput and Neelam Rajput are mutual person
- Bdr International FoundationActive 2 years 17 days
Jivansing Rajput and Neelam Rajput are mutual person
- Jj Plus Hospitals Private LimitedActive 7 years 5 months
Jivansing Rajput and Neelam Rajput are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bdr International Diagnostics?
Unlock and access historical data on people associated with Bdr International Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bdr International Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bdr International Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
